Abbott Laboratories(NYSE:ABT) Declares Dividend of $0.2600.

Abbott Laboratories (NYSE:ABT) had declared a cash dividend of $0.2600 on Sep 15, 2016. The shares will quote ex-dividend on Oct 12, 2016 and the record date has been fixed for Oct 14, 2016. On Sep 15, 2016 share price, the yield comes out to be 2.5484%. The dividend payable date has been fixed on Nov 15, 2016.

In a different note, On Sep 13, 2016, Jefferies said it Maintains its rating on Abbott Laboratories. In the research note, the firm Lowers the price-target to $52.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 4, 2016, Jefferies said it Maintains its rating on Abbott Laboratories. In the research note, the firm Raises the price-target to $49.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 14, 2016, Jefferies said it Maintains its rating on Abbott Laboratories. In the research note, the firm Raises the price-target to $45.00 per share. The shares have been rated ‘Buy’ by the firm. On Jun 21, 2016, Edward Jones said it Upgrades its rating on Abbott Laboratories. The shares have been rated ‘Buy’ by the firm.

Abbott Laboratories (ABT) shares turned negative on Tuesdays trading session with the shares closing down -0.1 points or -0.24% at a volume of 48,67,018. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $42. The peak price level was also seen at $42 while the days lowest was $41.58. Finally the shares closed at $41.58. The 52-week high of the shares is $46.38 while the 52-week low is $36. According to the latest information available, the market cap of the company is $61,122 M.

Abbott Laboratories(ABT) last announced its earnings results on Jul 20, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $5.33B. Analysts had an estimated revenue of $5.24B. Earnings per share were $0.55. Analysts had estimated an EPS of $0.53.

Several Insider Transactions has been reported to the SEC. On Jul 29, 2016, Stephen R Fussell (Executive Vice President) sold 41,500 shares at $45.01 per share price.Also, On Jul 27, 2016, Robert E Funck (Vice President, Controller) sold 26,800 shares at $43.08 per share price.On Jul 27, 2016, Michael J Warmuth (Executive Vice President) sold 26,800 shares at $43.49 per share price, according to the Form-4 filing with the securities and exchange commission.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.